|
[1]
|
Jiang F, Deng LH, Zhang LQ, Cai Y, Cheung CW, Xia ZY. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020;35(5):1545 − 9. http://dx.doi.org/10.1007/s11606-020-05762-wCrossRef
|
|
[2]
|
Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One 2020;15(6):e0234765. http://dx.doi.org/10.1371/journal.pone.0234765CrossRef
|
|
[3]
|
Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 2022;399(10335):1618 − 24. http://dx.doi.org/10.1016/S0140-6736(22)00327-0CrossRef
|
|
[4]
|
Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health 2021;6(5):e335 − 45. http://dx.doi.org/10.1016/S2468-2667(21)00055-4CrossRef
|
|
[5]
|
Chinese Center for Disease Control and Prevention. COVID-19 clinical and surveillance data — December 9, 2022 to February 13, 2023, China. 2023. https://weekly.chinacdc.cn/news/covid-surveillance/a6d95137-4b38-4c6b-9dee-b4a7b9e98965_en.htm. [2023-3-23].https://weekly.chinacdc.cn/news/covid-surveillance/a6d95137-4b38-4c6b-9dee-b4a7b9e98965_en.htm |
|
[6]
|
Pan Y, Wang L, Feng ZM, Xu H, Li F, Shen Y, et al. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. Lancet 2023;401(10377):664 − 72. http://dx.doi.org/10.1016/S0140-6736(23)00129-0CrossRef
|
|
[7]
|
Ceban F, Ling SS, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun 2022;101:93 − 135. http://dx.doi.org/10.1016/j.bbi.2021.12.020CrossRef
|
|
[8]
|
Di Mitri C, Arcoleo G, Mazzuca E, Camarda G, Farinella EM, Soresi M, et al. COVID-19 and non-COVID-19 pneumonia: a comparison. Ann Med 2021;53(1):2321 − 31. http://dx.doi.org/10.1080/07853890.2021.2010797CrossRef
|
|
[9]
|
Sun YM, Wang M, Lin WC, Dong W, Xu JG. Evolutionary analysis of Omicron variant BF.7 and BA.5.2 pandemic in China. J Biosaf Biosecur 2023;5(1):14 − 20. http://dx.doi.org/10.1016/j.jobb.2023.01.002CrossRef
|
|
[10]
|
Liu XH, Cheng T, Liu BY, Chi J, Shu T, Wang T. Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development. Front Pharmacol 2022;13:955648. http://dx.doi.org/10.3389/fphar.2022.955648CrossRef
|
|
[11]
|
Cao YL, Jian FC, Wang J, Yu YL, Song WL, Yisimayi A, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 2023;614(7948):521 − 9. http://dx.doi.org/10.1038/s41586-022-05644-7CrossRef
|
|
[12]
|
Velavan TP, Ntoumi F, Kremsner PG, Lee SS, Meyer CG. Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 - the public health challenges. Int J Infect Dis 2023;128:307 − 9. http://dx.doi.org/10.1016/j.ijid.2023.01.024CrossRef
|